• The fifteen-month dataset represents the final analysis from the Phase 1/2 study
• At the Month 15 primary timepoint, SKY-0515-treated patients showed a +1.59-point difference in Composite Unified Huntington’s Disease Rating Scale (cUHDRS) change from baseline versus overlap-weighted external natural history control
• Differences favoring SKY-0515 were statistically significant across all four cUHDRS components – Total Functional Capacity, Total Motor Score, Symbol Digit Modalities Test and Stroop Word Reading Test – and cUHDRS differences favored SKY-0515 at every prespecified timepoint in the study
• SKY-0515 has shown consistent average reductions in mutant huntingtin protein (mHTT) throughout the study of more than 60% at the 9 mg dose  
• SKY-0515 has shown consistent average reductions in PMS1 mRNA of more than 25% at the 9 mg dose
• The Company’s Phase 1/2 program and global Phase 2/3 FALCON-HD 004-ANZ + 004-WW pivotal program for Huntington’s disease now have enrolled over 200 patients across twenty trial sites in ten countries.

BOSTON, Sept. 16, 2026 /PRNewswire/ — Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced final fifteen-month results from its Phase 1/2 clinical trial evaluating SKY-0515, an investigational oral treatment for Huntington’s disease (HD).

The Phase 1/2 patient study is a randomized, double-blind, placebo-controlled parallel-group study evaluating two dose levels of SKY-0515 in patients over twelve weeks, followed by a twelve-month blinded Extension period during which all participants receive active treatment at either a low or high dose (4mg or 9mg), with the majority of patients on the 9 mg dose.

At Month 15, the primary timepoint, patients treated with SKY-0515 improved on the cUHDRS by an average of 0.94 points from where they started, while a comparison group of untreated patients from the Enroll-HD natural history database declined by an average of 0.65 points. The gap between the two groups was 1.59 points (95% CI: 1.09, 2.09; p<0.001).

SKY-0515 patients also did better than the comparison group on each of the four measures that make up the cUHDRS: daily function (Total Functional Capacity, +0.98 points), movement (Total Motor Score, −9.38 points, where a lower score is better), processing speed (Symbol Digit Modalities Test, +4.15 points) and reading speed (Stroop Word Reading Test, +4.18 points). All differences were statistically significant.

Table 1. Change from baseline at Month 15 in cUHDRS and its components, SKY-0515 versus overlap-weighted external control

CI = confidence interval; SE = standard error.

The same pattern held throughout the study. At every scheduled checkpoint, SKY-0515 patients were doing better on the cUHDRS than the comparison group: 0.66 points at Month 3, 0.78 points at Month 6, 1.04 points at Month 9, 0.79 points at Month 12 and 1.59 points at Month 15. The difference was statistically significant from Month 9 onward.

On average, SKY-0515-treated patients’ cUHDRS scores held at or above their baseline level at every assessment through Month 15, while the external comparison group’s average score declined from Month 6 onward.

Table 2. Change from baseline in cUHDRS by timepoint, SKY-0515 versus overlap-weighted external control

CI = confidence interval; SE = standard error. See footnote¹ for data analysis discussion.

SKY-0515 has shown consistent average reductions of more than 60% mutant huntingtin protein (mHTT) and 25% PMS1 mRNA in patients at the 9 mg dose throughout the study. Mutant huntingtin is the primary protein responsible for HD pathology, while PMS1 is a key driver of somatic CAG repeat expansion associated with disease progression.

SKY-0515 has demonstrated excellent central nervous system exposure and has been generally well tolerated across all dose levels studied through fifteen months of treatment, with no treatment-related SAEs. 

“Skyhawk’s Phase 1/2 results are extremely encouraging clinical data. A 1.59-point cUHDRS difference versus a rigorously weighted natural history control at fifteen months is exactly the type of signal the field looks for in early studies of a potentially effective therapeutic agent. The consistent effects on function, motor and cognitive measures need to be further studied in ongoing placebo-controlled studies but it is an exciting step forward for HD and the program,” said Dr. Samuel Frank, Director of the Huntington’s Disease Society of America Center of Excellence at Beth Israel Deaconess Medical Center. “SKY-0515’s dual reduction of mHTT and PMS1 addresses two core pathogenic mechanisms of Huntington’s disease. If these findings are confirmed in the ongoing Phase 2/3 FALCON-HD pivotal program, the impact on people living with HD across the world could be profound.”

“For almost two decades, I have fought as an advocate for Huntington’s disease patients, bearing witness to countless heartbreaking trial setbacks that have let our families down. To finally see results like these—patients experiencing improvements in function, movement, and cognition — is what we have been hoping and waiting for,” said Katie Jackson, Chief Executive Officer of Help 4 HD International. “What makes SKY-0515 especially exciting is that it is a pill, taken once a day at home. Every step forward in HD matters and we celebrate all of them, but a therapy that is noninvasive and does not require care in a specialized center has the potential to reach so many more patients – in rural communities, in families who can’t travel, and across the world where care is hard to come by.

My husband didn’t get a treatment in time. I am hopeful that my children and the children of thousands of families like ours will. We are the generation of change, and Skyhawk’s drug, if these promising results are fully confirmed in future trials, is what change looks like.”

“The completion of this Phase 1/2 study with SKY-0515, showing statistically significant clinical benefit across every cUHDRS component, is a powerful demonstration of what Skyhawk’s SKYSTAR^® platform can achieve: a daily pill, taken at home, that modifies RNA splicing to lower disease-causing proteins in the CNS and systemically throughout the body,” said Sergey Pauskin, Co-founder and Head of R&D at Skyhawk. “We are applying the same platform to a series of challenging neurological diseases now advancing toward human trials, and the data from SKY-0515 confirms that the possibilities of extraordinary novel drugs generated by Skyhawk’s SKYSTAR platform are very exciting.”

Huntington’s disease is a rare, hereditary, and ultimately fatal neurodegenerative disorder affecting more than 40,000 symptomatic individuals in the United States, with hundreds of thousands impacted worldwide. There are currently no approved therapies shown to slow or halt disease progression.

SKY-0515 is an orally administered investigational small molecule RNA splicing modifier developed using the company’s proprietary SKYSTAR platform. SKY-0515 is designed to reduce both mHTT and PMS1 proteins.

The worldwide Phase 2/3 FALCON-HD-004-WW pivotal study is now active across more than ten countries and twenty clinical sites. SKY-0515’s Phase 1/2 and FALCON-HD pivotal studies have now enrolled more than 200 patients.

Skyhawk expects to advance additional novel therapies targeting rare neurological diseases with no approved disease-modifying treatment into clinical development by the end of 2027.

About the Fifteen-Month Analysis
Phase 1/2 cUHDRS LS mean change from baseline versus external control at 3, 6, 9, 12 and 15 months, and cUHDRS subcomponents LS mean change from baseline versus external control at 15 months, were estimated via overlap-weighted ANCOVA for patients receiving SKY-0515 once daily. Nominal timepoints are anchored to a participant’s first dose of SKY-0515 (Day 1 to Month 3: n=24, Month 6: n=20, Month 9: n=20, Month 12: n=18, Month 15: n=15). Overlap-weighted propensity score weighting was performed using Enroll-HD, 2CARE and CREST-E datasets (Month 3: n=21, Month 6: n=180, Month 9: n=588, Month 12: n=3569, Month 15: n=1337).

Participants received placebo, 3 mg or 9 mg during the first 3 months; afterwards, all participants received 4 mg or 9 mg following Extension-phase randomization. The Month 15 decline in participants partly reflects study design, as the 12-month Extension period caps SKY-0515 exposure at 12 months for participants who initially received 3 months of placebo.

The primary analysis includes all eligible participants with an available Month 15 cUHDRS assessment. Per the study’s statistical analysis plan, a small number of participant-timepoints were excluded following a qualifying intercurrent event — onset of an unrelated medical condition, initiation of a medication that could confound assessment of treatment effect, or a change in background Huntington’s disease therapeutic intervention.

About SKY-0515’s Phase 1/2 Clinical Program
SKY-0515’s Phase 1/2 clinical trial is a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKY-0515 in healthy volunteers and patients with early-stage Huntington’s disease (HD).

The trial consists of three parts. Parts A and B evaluated SKY-0515 in Healthy Volunteers. Part C is a randomized, double-blind, placebo-controlled parallel-group study evaluating two dose levels of SKY-0515 in patients with early-stage HD (HD-ISS Stage 1, Stage 2, or mild Stage 3) over 84 days, followed by a twelve-month blinded Extension period during which all participants receive active treatment at either a low or high dose.

Study assessments include measurements of mutant HTT protein, PMS1 mRNA, and cUHDRS.  Enrollment and treatment in the Phase 1/2 study are complete, and the fifteen-month analysis represents the final clinical dataset from the study.

About SKY-0515’s Phase 2/3 FALCON-HD (004-ANZ and 004-WW) Pivotal Program
The FALCON-HD pivotal program (NCT06873334 and NCT07378644) is a randomized, double-blind, placebo-controlled, dose-ranging study evaluating the pharmacodynamics, safety and efficacy of SKY-0515. Eligible patients receive once-daily oral SKY-0515 at one of three dose levels or placebo.

FALCON-HD 004-ANZ enrolled 144 participants with Stage 2 and Stage 3 HD across sites in Australia and New Zealand. Enrollment is complete.

FALCON-HD 004-WW plans to enroll approximately 600 participants with Stage 2 and Stage 3 HD across more than 40 sites worldwide and is actively recruiting.

Additional information regarding FALCON-HD, including participating sites and eligibility criteria, is available at ClinicalTrials.gov and www.FALCON-HD.com.

About Skyhawk Therapeutics
Skyhawk Therapeutics is a clinical-stage biotechnology company leveraging its proprietary SKYSTAR^® platform to discover and develop small molecule RNA-modulating therapies for the world’s most intractable diseases. For more information, visit www.skyhawktx.com.

Skyhawk Contact
Maura McCarthy
Head of Corporate Development
maura@skyhawktx.com 

¹Phase 1/2 cUHDRS LS mean change from baseline vs. external control at 3, 6, 9, 12 and 15 months, estimated via overlap-weighted ANCOVA, for patients receiving SKY-0515 once-daily. Nominal timepoints are anchored to each participant’s first dose of SKY-0515 (Day 1 to Month 3: n=24, Month 6: n=20, Month 9: n=20, Month 12: n=18, Month 15: n=15). Participants received placebo, 3 mg or 9 mg during the first 3 months; afterwards, all participants received 4 mg or 9 mg following Extension-phase randomization. Overlap-weighted propensity score weighting was performed using Enroll-HD, 2CARE and CREST-E datasets (Month 3: n=21, Month 6: n=180, Month 9: n=588, Month 12: n=3569, Month 15: n=1337).

Note: The Month 15 decline in participants partly reflects study design, as the 12-month Extension period caps SKY-0515 exposure at 12 months for the participants who initially received 3 months of placebo. The primary analysis includes all eligible participants with an available Month 15 cUHDRS assessment. Per the study’s statistical analysis plan, a small number of participant-timepoints were excluded following a qualifying intercurrent event — onset of an unrelated medical condition, initiation of a medication that could confound assessment of treatment effect, or a change in background Huntington’s disease therapeutic intervention.

The 17,700-lumen lighting system combines long-range trail illumination with app-controlled pixel text, graphics and animations

DALLAS, Sept. 16, 2026 /PRNewswire/ — Wolfbox, a leader in off-road dash cams and automotive electronics, introduces the new NomadPixel 5, the world’s first programmable off-road pixel lighting system that brings customizable pixel displays to high-performance trail lights for SUVs and pickup trucks. Designed for off-road and overlanding enthusiasts, the system enables drivers to create text, graphics and animated content from their phones and display it outdoors with 8,850 raw lumens of illumination per light.

From September 15 to September 29, the NomadPixel 5 is available for presale from the Wolfbox website at an early-bird price of US$499 with the code NPLIGHT100. The official launch follows on September 30, when the system will be offered at its regular retail price of US$639.

Off-road lights have traditionally served only one purpose: visibility. With fixed beams, drivers have little opportunity to change how the lights look or what they display. NomadPixel 5 takes this familiar piece of trail equipment in a new direction. Each of the NomadPixel 5’s two five-inch lights doubles as a programmable display, giving drivers a way to illuminate the road ahead, personalize their vehicles and share visible messages with others in their group, lighting up every moment of their trip.

The lights are controlled via the Wolfbox mobile app and can be configured independently. Users can choose from preset graphics, type their own text or draw an original design one pixel at a time. Messages and graphics can remain static, scroll across the display or flicker. Three animation speeds and four brightness settings (40%, 60%, 80% and 100%) provide further control over how the content appears.

The customization feature can be used in plenty of ways beyond the trail itself. Drivers might display a vehicle or club name at an off-road gathering, create graphics for a competition or celebration, or add a personal touch to an overlanding campsite. The content can be changed for each trip or occasion, without replacing the lights or installing a separate display.

In remote areas, the pixel displays can also serve as another form of visible communication. A driver who becomes separated from a group or gets stuck outside reliable mobile coverage can display “HELP” or “SOS” messages to attract attention from other off-roaders at a distance.

Beyond creative functions, NomadPixel 5 is a capable trail lighting system. Its two lights each produce 8,850 raw lumens, and the driving beam reaches 1 lux at 275 meters. Output levels can be adjusted to suit nighttime trails, campsites or group-driving conditions.

The NomadPixel 5 is also built for the weather and terrain that come with off-road travel. The lights carry an IP69K rating and use waterproof breather valves to protect against water, mud, dust and severe weather. They can operate in temperatures ranging from −40°F to 149°F (−40°C to 65°C).

ADC12 powder-coated die-cast aluminum housings, UV-coated polycarbonate panels and U-shaped stainless-steel mounting brackets add another layer of durability. The design has undergone 136 hours of salt-spray testing, while the LEDs have an estimated operating life of approximately 50,000 hours. Wolfbox backs NomadPixel 5 with a five-year warranty.

The system is designed for broad use across a wide range of off-road SUVs and pickup trucks, subject to individual mounting configurations. Amber and clear lens covers are included, allowing drivers to adapt the lights to changing conditions and preferences.

About Wolfbox

Founded in 2019, Wolfbox is a leading brand in automotive electronics that specializes in advanced smart mirrors and dash cams, as well as other auto accessories such as jump starters, tire inflators and deflators, 2-in-1 starters and compressors, and more. Wolfbox has served over 800,000 drivers in 89 countries, and continues to innovate and revolutionize the auto accessories market with high-tech automotive gadgets and electronics for tech-savvy consumers and outdoor activity enthusiasts.

For more information, visit wolfbox.com and gears.wolfbox.com.

Regional Energy Leaders Gather to Drive Collaboration for a Sustainable Energy Future

HONG KONG, Sept. 15, 2026 /PRNewswire/ — CLP Power Hong Kong Limited (CLP Power) hosted the Association of the Electricity Supply Industry of East Asia and the Western Pacific (AESIEAP) CEO Conference 2026 in Hong Kong from 14 – 16 September, bringing together over 200 leaders from the power and energy sector, government officials, policymakers, technology companies, research institutions and industry partners from across the region. The three-day Conference featured plenary sessions, roundtable discussions, business matching sessions and technical visits.

Under the theme “Transforming Energy with Intelligence”, the Conference provided a platform to discuss how the industry can respond to rising electricity demand, climate challenges and increasingly complex power systems, while strengthening energy system resilience, accelerating smart energy development and advancing a reliable, affordable and low-carbon energy future.

As CLP Power assumes the AESIEAP presidency for the 2026–2027 term, it aims to accelerate the Asia-Pacific region’s energy transition through four priorities: fostering high-level multilateral dialogue, promoting technology and knowledge sharing, advancing regional decarbonisation, and unlocking new opportunities for business collaboration.

AESIEAP President and CLP Power Managing Director Mr Joseph Law said, “The next phase of the energy transition will not be delivered by infrastructure alone, nor by technology alone. It will require intelligence in the technologies we deploy, the grids we operate, the decarbonisation choices we make and the partnerships that carry innovation from pilot projects to system-wide impact. Through the AESIEAP CEO Conference 2026, we hope to work with our regional partners to build a more resilient energy future, power a new era of smart energy and shape an open and collaborative energy ecosystem, translating regional collaboration into progress at the speed and scale required.”

The Financial Secretary of the Hong Kong Special Administrative Region, the Honourable Paul Chan Mo-po, officiated at the conference as the Guest of Honour. He said, “over the next two to three decades, Asia will play an increasingly important role in global development. As our economies expand, electrification gathers pace and AI becomes more widely used, our energy needs will continue to grow. Hong Kong is determined to play our part as the ‘super connector’ and ‘super value-adder’ by deepening collaboration across borders and sectors, making green standards work better across markets, and strengthening regional energy co-operation. Together, we can provide the power our economies need and build a cleaner, more secure future for the generations to follow.”

CLP Holdings Chief Executive Officer Mr T.K. Chiang remarked, “This year’s AESIEAP CEO Conference comes at an important time for the power industry. As the energy transition is entering a more demanding phase, intelligence must be more than an aspiration. It must become an operating capability: the way we plan, invest, manage our systems and serve our customers. This is where intelligence becomes indispensable – bringing these together for a cleaner, more resilient and more sustainable future.”

World Energy Council Chair, Asia and Sembcorp Industries Group President & CEO Mr Wong Kim Yin highlighted in his keynote speech that, “Intelligence is not only changing how energy is consumed. It is also changing where demand is growing, how we operate energy systems, and what infrastructure will be required. Our task is to harness intelligence to operate better, and to build the reliable power capacity digital growth requires.”

Established in 1975, AESIEAP is a non-governmental organisation dedicated to promoting exchanges and cooperation in the Asia-Pacific power industry. Its members come from countries and regions including China, Indonesia, Korea, Malaysia, the Philippines, Singapore and Thailand. As a founding member of AESIEAP, CLP has long been committed to driving knowledge sharing and regional collaboration across the Association. Hong Kong hosted AESIEAP events in 1975, 1977 and 1991, and this year marks the fourth time the city has welcomed the Association’s flagship gathering. Building on the momentum of the CEO Conference 2026, Hong Kong will host another major AESIEAP event, the Conference of the Electric Power Supply Industry (CEPSI) 2027, next year, providing a broader platform for the region’s energy community to deepen exchanges and collaboration.

This acquisition unlocks an extraordinary new era of exploration across air, land and sea

NEW YORK, Sept. 15, 2026 /PRNewswire/ — Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND), a global adventure travel company offering immersive, educational expeditions to over 100 destinations across all seven continents, today announced it has acquired a majority ownership of White Desert, the pioneering luxury Antarctic company and Echo Charlie, a new aviation travel brand providing specialized access to unique destinations worldwide.

Established in 2005 by record-breaking polar explorer, Patrick Woodhead, White Desert flies clients into the remote interior of Antarctica, blending logistical precision with a level of comfort previously unheard of on the ice. Billed as the ultimate bucket-list adventure, their itineraries include a journey to the Geographic South Pole and a visit to an Emperor penguin colony of over 20,000 birds.

“While this is the largest transaction in the history of the company, it is much more than a business deal—it is a powerful partnership between two businesses that have spent decades pushing the boundaries of what experiential travel can be,” said Natalya Leahy, Chief Executive Officer of Lindblad Expeditions Holdings, Inc.

This strategic acquisition marks the beginning of an exciting new chapter in Antarctic travel. Leveraging their shared expertise, Lindblad Expeditions and White Desert see significant opportunities to expand White Desert’s extraordinary offering—with the development of camps and guest experiences and bolstering their logistical capabilities.

“Having spent the last 20 years pioneering tourism in the interior, we are privileged to join forces with people who did exactly the same thing, only 40 years earlier on the coastline of Antarctica. With a shared ethos for small-scale, responsible travel, we are thrilled for what lies ahead,” said Patrick Woodhead, Founder and Chairman of White Desert.

Through their global platform and expertise, Lindblad Expeditions will also support the development and growth of a brand-new offering – Echo Charlie. Inspired by the golden age of aviation aboard a fully restored DC-3 (an aircraft that can land on remote airstrips without the hassle of commercial airports), this new offering fuses real life adventure with the seamless connection of highly diverse landscapes.

“Taking our aviation expertise beyond Antarctica, Echo Charlie’s collection of itineraries explores the far reaches of the globe, from Colombia to Patagonia, the Faroe Islands to Greenland. This is genuine adventure, made safe and accessible—the only question is where we go next,” said Woodhead.  

“Echo Charlie delivers on what most of us only read about in childhood stories—flying to hidden places, uncovering the secrets of ancient cultures, and experiencing the breathtakingly diverse landscapes,” said Leahy. “By combining Patrick’s aviation expertise with our global platform and deep shared spirit of innovation, we are about to enter a new chapter entirely—more awe-inspiring experiences to more guests in more places on this planet.”

Patrick Woodhead will serve as Chairman of White Desert and CEO of Echo Charlie, while also joining Lindblad Expeditions as Strategic Innovation Advisor. His expertise in aviation and exploration will help inform future innovation, responsible growth and new guest experiences across the Lindblad portfolio.

Like other companies that have joined the Lindblad family, White Desert and Echo Charlie will continue to operate as a stand-alone offering, preserving their founder-led vision and distinctive culture, while benefiting from the reach, capabilities and resources of Lindblad Expeditions.

“Over the last decade, our ambition has been to build a global platform of exceptional experiential travel brands, fueled by expertise, passion and innovation, and led by iconic founders,” said Mark Ein, Co-Chair of the Board. “The acquisition of White Desert and Echo Charlie now adds an extraordinary set of pinnacle journeys to our guests”.

Transaction Details
Lindblad Expeditions acquired a majority stake of 60% in White Desert and Echo Charlie for an aggregate cash purchase price of approximately $61 million, plus approximately $6 million for cash on the balance sheet and subject to customary true-up adjustments for working capital, cash and indebtedness. This investment advances Lindblad Expeditions’ strategy of building a diversified portfolio of differentiated adventure travel experiences. Baird served as exclusive financial advisor to White Desert and Echo Charlie in the transaction.

Updated Guidance
Lindblad Expeditions also raises its full-year 2026 revenue, net yield, and Adjusted EBITDA guidance to reflect the acquisitions of White Desert and Echo Charlie, as well as continued strong performance across the business.

“Our updated guidance reflects both an exciting new chapter for our company with the addition of White Desert and Echo Charlie to our global platform of experiential travel brands and, importantly, the continued strong momentum of our underlying business as well as the strength of our business model,” said Natalya Leahy, Chief Executive Officer of Lindblad Expeditions.

The Company’s current expectations for the full year 2026 are as follows:

• Tour revenues of $850 – $880 million
• Net Yield per Available Guest Night of 5.5% – 6.5%
• Adjusted EBITDA of $140 – $148 million

About Lindblad Expeditions Holdings, Inc.
Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND; the “Company”) is a leader in global expedition travel, offering immersive, educational journeys that span all seven continents through its eight pioneering brands. Driven by a passion for the planet and the belief that there is always more to be discovered, the Company leads travelers to the farthest reaches of the world with an expansive portfolio of air, land and sea-based expeditions. In collaboration with National Geographic, Lindblad Expeditions operates and sells the National Geographic-Lindblad Expeditions co-brand, which offers ship-based voyages that allow guests to explore remote destinations alongside scientists and naturalists, and with state-of-the-art exploration tools. In addition to its renowned modern expedition cruises, the Company’s award-winning land-based brands—Natural Habitat Adventures, Off the Beaten Path, DuVine Cycling + Adventure Co., Classic Journeys, Wineland-Thomson Adventures, White Desert and Echo Charlie—provide extraordinary wildlife, cultural, and adventure-focused experiences. Together, these brands connect travelers with some of the planet’s most inspiring natural and cultural landscapes, fostering a deep appreciation for the world. To learn more about Lindblad Expeditions Holdings, Inc., its growing portfolio of brands, and the Company’s commitment to responsible exploration, visit investors.expeditions.com

About White Desert
White Desert was founded in 2005 by record-breaking polar explorer Patrick Woodhead to make the interior of Antarctica accessible to guests from around the world. Today, the company employs over 150 staff representing 18 different nationalities and continues to lead the industry in aviation, safety, and sustainable luxury travel. For more information, visit white-desert.com

About Echo Charlie
Echo Charlie runs luxury adventure journeys aboard a fully-refurbished vintage DC-3, carrying 12 guests at a time into some of the world’s least-reached regions. Its journeys connect remote landscapes and cultures in a single arc, pairing real adventure with laidback comfort. It offers rare access, the assurance of safety, and moments of genuine awe that restore a sense of wonder at the world. For more information, visit echo-charlie.com

Non-GAAP Financial Measures
The Company uses a variety of operational and financial metrics, including non-GAAP financial measures such as Adjusted EBITDA, Occupancy, Net Yields and Net Cruise Costs, to enable it to analyze its performance and financial condition. The Company utilizes these financial measures to manage its business on a day-to-day basis and believes that they are the most relevant measures of performance. Some of these measures are commonly used in the cruise and tourism industry to evaluate performance. The Company believes these non-GAAP measures provide expanded insight to assess revenue and cost performance, in addition to the standard GAAP-based financial measures. There are no specific rules or regulations for determining non-GAAP measures, and as such, they may not be comparable to measures used by other companies within the industry.

The presentation of non-GAAP financial information should not be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The definitions of non-GAAP financial measures along with a reconciliation of non-GAAP financial information to GAAP are included in the supplemental financial schedules.

Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, the Company’s expectations regarding the expected benefits of the transaction with White Desert and Echo Charlie and the Company’s updated financial guidance and may also generally be identified as such because the context of such statements will include words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or words of similar import. Similarly, statements that describe the Company’s financial guidance or future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties that could cause results to differ materially from those expected. It is not possible to predict or identify all such risks. There may be additional risks that we consider immaterial or which are unknown. These factors include, but are not limited to, the following: (i) adverse general economic and/or geopolitical factors that negatively impact the ability or desire of people to travel; (ii) loss of business due to competition; (iii) unscheduled disruptions in our business due to travel restrictions, weather events, mechanical failures, crew or guest illness such as gastrointestinal, pandemics, geopolitical issues or other events; (iv) increases in fuel prices, changes in fuel consumed and availability of fuel supply in the geographies in which we operate or in general; (v) the loss of key employees, our inability to recruit or retain qualified shoreside and shipboard employees and increased labor costs; (vi) the impact of delays or cost overruns with respect to anticipated or unanticipated drydock, maintenance, modifications or other required construction related to any of our vessels; (vii) management of our growth and our ability to execute our planned growth, including our ability to successfully integrate any future acquisitions; (viii) our ability to maintain our relationships with National Geographic and/or World Wildlife Fund; (ix) compliance with new and existing laws and regulations, including environmental regulations and travel advisories and restrictions; (x) our substantial indebtedness and our ability to remain in compliance with the financial and/or operating covenants in such arrangements; (xi) the impact of material litigation, enforcement actions, claims, fines or penalties on our business; (xii) the impact of severe or unusual weather conditions, including climate change, on our business; (xiii) adverse publicity regarding the travel and cruise industry in general, the safety of travel, or passenger and crew illnesses such as gastrointestinal illness or other health issues; (xiv) the result of future financing efforts; and (xv) those risks described in the Company’s filings with the SEC. Stockholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect the Company’s performance may be found in its filings with the SEC, which are available at http://www.sec.gov or at http://www.expeditions.com in the Investor Relations section of the Company’s website.